← All trials
NCT00615173
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2006
- Primary completion
- Sep 1, 2008
- Completion date
- Sep 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 81
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Sun Yat-Sen UniversityLead sponsor
- Guangxi Medical UniversityOverall official - principal investigator
- Sichuan UniversityOverall official - principal investigator
- Southern Medical UniversityOverall official - principal investigator
- Guangzhou Medical UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- The First People's Hospital of Yunan ProvinceOverall official - principal investigator
- 1st People's Hospital of FoshanOverall official - principal investigator
- Sun Yat-Sen UniversityOverall official - principal investigator
- Shantou UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.